In fact, it should be considered that mTOR inhibitors act both on tumor and on immune cells; thus, one can hypothesize that the putative anti-tumor efficacy of mTOR inhibitors on cancer cells might be counterbalanced by their suppressive effects on immune cells, thereby building an immunosuppressive environment that facilitates tumor progression [12,13]. This evidence concerns the gene MTOR and cancer.